Effects of recombinant Clara cell secretory protein (rhCC10) on inflammatory-related matrix metalloproteinase activity in a preterm lamb model of neonatal respiratory distress

Pediatric Critical Care Medicine

Volumn 8, Issue 1, 2007, Pages 40-46

  Miller, Thomas L ^a,b,c   Shashikant, Beth N ^a   Pilon, Aprile L ^d   Pierce, Richard A ^e   Shaffer, Thomas H ^a,b   Wolfson, Marla R ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Claragen Inc   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clara cell secretory protein (CC10); Lung structure; Matrix metalloproteinase; Mechanical ventilation; Surfactant

Indexed keywords

BERACTANT; CLARA CELL PROTEIN; GELATINASE A; GELATINASE B; MATRILYSIN; RECOMBINANT PROTEIN; SURFACTANT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; CARDIOPULMONARY FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; GESTATIONAL AGE; IN VITRO STUDY; LAMB; LUNG COMPLIANCE; LUNG FUNCTION; MORPHOMETRICS; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; PREMATURITY; PRIORITY JOURNAL;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; INFANT, NEWBORN; LUNG; LUNG COMPLIANCE; METALLOPROTEASES; PROTEASE INHIBITORS; PULMONARY ALVEOLI; PULMONARY SURFACTANTS; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SHEEP; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TREATMENT OUTCOME; UTEROGLOBIN;

EID: 33846501491     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000253022.10607.61     Document Type: Article

References (33)

1. Parks WC, Shapiro SD: Matrix metalloproteinases in lung biology. Respir Res 2001; 2:10-19
2. Tambunting F, Beharry KD, Hartleroad J, et al: Increased lung matrix metalloproteinase-9 levels in extremely premature baboons with bronchopulmonary dysplasia. Pediatr Pulmonol 2005; 39:5-14
3. Danan C, Jarreau PH, Franco ML, et al: Gelatinase activities in the airways of premature infants and development of bronchopulmonary dysplasia. Am J Physiol 2002; 283: L1086-L1093
4. Dik WA, De Krijger RR, Bonekamp L, et al: Localization and potential role of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 and -2 in different phases of bronchopulmonary dysplasia. Pediatr Res 2001; 50:761-766
5. Ikegami M, Jobe A, Jacobs H, et al: A protein from airways of premature lambs that inhibits surfactant function. J Appl Physiol 1984; 57:1134-1142
6. Holm BA, Notter RH: Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol 1987; 63: 1434-1442
7. Ryerse JS, Hoffmann JW, Mahmoud S, et al: Immunolocalization of cc10 in clara cells in mouse and human lung. Histochem Cell Biol 2001; 115:325-332
8. Pilon AL: Rationale for the development of recombinant human cc10 as a therapeutic for inflammatory and fibrotic disease. Ann N Y Acad Sci 2000; 923:280-299
9. Levin SW, Butler JD, Schumacher UK, et al: Uteroglobin inhibits phospholipase a2 activity. Life Sci 1986; 38:1813-1819
10. Duncan JE, Hatch GM, Belik J: Susceptibility of exogenous surfactant to phospholipase a2 degradation. Can J Physiol Pharmacol 1996; 74:957-963
11. Geerts L, Jorens PG, Willems J, et al: Natural inhibitors of neutrophil function in acute respiratory distress syndrome. Crit Care Med 2001; 29:1920-1924
12. Shashikant BN, Miller TL, Welch RW, et al: Dose response to rhcc10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome: Physiological, inflammatory, and kinetic profiles. J Appl Physiol 2005; 99:2204-2211
13. Miller TL, Shashikant BN, Melby JM, et al: Recombinant human clara cell secretory protein in acute lung injury of the rabbit: Effect of route of administration. Pediatr Crit Care Med 2005; 6:698-706
14. Levine CR, Gewolb IH, Allen K, et al: The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 2005; 58:15-21
15. Chandra S, Davis JM, Drexler S, et al: Safety and efficacy of intratracheal recombinant human clara cell protein in a newborn piglet model of acute lung injury. Pediatr Res 2003; 54:509-515
16. Wolfson MR, Kechner NE, Roache RF, et al: Perfluorochemical rescue after surfactant treatment: Effect of perflubron dose and ventilatory frequency. J Appl Physiol 1998; 84: 624-640
17. Bhutani VK, Sivieri EM, Abbasi S, et al: Evaluation of neonatal pulmonary mechanics and energetics: A two factor least mean square analysis. Pediatr Pulmonol 1988; 4:150-158
18. Antunes MJ, Cullen JA, Holt WJ, et al: Continued pulmonary recovery observed after discontinuing extracorporeal membrane oxygenation. Pediatr Pulmonol 1994; 17: 143-148
19. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37:911-917
20. Bartlett GR: Phosphorus assay in column chromatography. J Biol Chem 1959; 234: 466-468
21. Rouser G, Fleischer S, Yamamoto A: Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5:494-496
22. Enhorning G: Pulsating bubble technique for evaluating pulmonary surfactant. J Appl Physiol 1977; 43:198-203
23. Wolfson MR, Greenspan JS, Deoras KS, et al: Comparison of gas and liquid ventilation: Clinical, physiological, and histological correlates. J Appl Physiol 1992; 72:1024-1031
24. Miller TL, Touch SM, Singhaus CJ, et al: Expression of matrix metalloproteinases 2, 7 and 9, and their tissue inhibitors 1 and 2, in developing rabbit tracheae. Biol Neonate 2006; 89:236-243
25. Auten RL, Notter RH, Kendig JW, et al: Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991; 87: 101-107
26. Dreyfuss D, Saumon G: Ventilator-induced lung injury: Lessons from experimental studies. Am J Respir Crit Care Med 1998; 157: 294-323
27. Kheradmand F, Rishi K, Werb Z: Signaling through the egf receptor controls lung morphogenesis in part by regulating mt1-mmp-mediated activation of gelatinase a/mmp2. J Cell Sci 2002; 115:839-848
28. Gibbs DF, Shanley TP, Warner RL, et al: Role of matrix metalloproteinases in models of macrophage-dependent acute lung injury. Evidence for alveolar macrophage as source of proteinases. Am J Respir Cell Molec Biol 1999; 20:1145-1154
29. Allan JA, Docherty AJ, Barker PJ, et al: Binding of gelatinases a and b to type-i collagen and other matrix components. Biochem J 1995; 309:299-306
30. Dunsmore SE, Saarialho-Kere UK, Roby JD, et al: Matrilysin expression and function in airway epithelium. J Clin Invest 1998; 102: 1321-1331
31. Wilson CL, Matrisian LM: Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996; 28:123-136
32. Li Q, Park PW, Wilson CL, et al: Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002; 111:635-646
33. Su WY, Jaskot RH, Richards J, et al: Induction of pulmonary matrilysin expression by combustion and ambient air particles. Am J Physiol 2000; 279:L152-L160